NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

ONCY

Oncolytics Biotech, Inc

Jun 30 • 04:00PM ET

0.7730

Dollar change +0.0224
Percentage change 2.98	%

Healthcare • Biotechnology • Canada • NASD

Peers: CRSP NTLA EDIT BLUE CLLS FATE IOVA ADAP PSTX TCRT

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.29	Insider Own	3.20%	Shs Outstand	86.42M	Perf Week	21.35%
Market Cap	68.66M	Forward P/E	-	EPS next Y	-0.28	Insider Trans	0.00%	Shs Float	85.98M	Perf Month	112.13%
Enterprise Value	58.72M	PEG	-	EPS next Q	-0.07	Inst Own	10.75%	Short Float	3.03%	Perf Quarter	28.83%
Income	-22.69M	P/S	-	EPS this Y	4.14%	Inst Trans	3.91%	Short Ratio	3.41	Perf Half Y	-20.31%
Sales	0.00M	P/B	14.81	EPS next Y	-0.56%	ROA	-115.29%	Short Interest	2.61M	Perf YTD	-15.41%
Book/sh	0.05	P/C	6.46	EPS next 5Y	10.74%	ROE	-211.24%	52W High	1.53 -49.48%	Perf Year	-25.67%
Cash/sh	0.12	P/FCF	-	EPS past 3/5Y	8.27% 23.13%	ROIC	-453.37%	52W Low	0.33 137.26%	Perf 3Y	-24.41%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.71% 14.03%	Perf 5Y	-62.29%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	3.28%	Oper. Margin	-	ATR (14)	0.07	Perf 10Y	-85.34%
Dividend Ex-Date	-	Quick Ratio	3.21	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	72.00	Recom	1.40
Dividend Gr. 3/5Y	- -	Current Ratio	3.21	EPS Q/Q	18.85%	SMA20	36.41%	Beta	1.01	Target Price	3.88
Payout	-	Debt/Eq	0.15	Sales Q/Q	-	SMA50	46.44%	Rel Volume	0.86	Prev Close	0.75
Employees	28	LT Debt/Eq	0.11	Earnings	May 14 AMC	SMA200	-1.07%	Avg Volume	765.13K	Price	0.77
IPO	Oct 05, 2001	Option/Short	No / Yes	EPS/Sales Surpr.	17.82% -	Trades		Volume	654,815	Change	2.98%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-06-22	Initiated	Maxim Group	Buy	$3
Feb-17-21	Initiated	H.C. Wainwright	Buy	$15

Jun-30-25 11:02AM	Oncology Innovation Just Hit a Turning Point -- Here's What to Watch (PR Newswire)
07:00AM	Oncolytics Biotech Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy (PR Newswire)
Jun-26-25 11:44AM	The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough? (PR Newswire)
Jun-24-25 12:52PM	Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices (PR Newswire) +5.79%
Jun-20-25 09:21AM	With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology (PR Newswire) -6.74%
11:19AM	Loading…
Jun-18-25 11:19AM	Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going (PR Newswire) +10.76%
Jun-12-25 10:00AM	As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry (PR Newswire)
09:00AM	After Major Oncology Conference, All Eyes Turn to Industry Innovation (PR Newswire)
Jun-11-25 07:00AM	Oncolytics Biotech Names New CEO to Accelerate Momentum in Immunotherapy Programs (PR Newswire) +34.10%
May-23-25 09:10AM	New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs (PR Newswire)
07:00AM	Oncolytics Biotech to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities (PR Newswire)
May-15-25 03:15AM	Oncolytics Biotech Inc (ONCY) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
May-14-25 04:01PM	Oncolytics Biotech Reports First Quarter Financial Results and Highlights Clinical Momentum (PR Newswire)
May-06-25 07:00AM	Oncolytics Biotech to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights (PR Newswire) -6.42%
May-01-25 11:04AM	New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty (PR Newswire)
07:00AM	Loading…
Apr-24-25 07:00AM	Oncolytics Biotech to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action (PR Newswire)
Apr-14-25 10:15AM	With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz (PR Newswire) -5.28%
Apr-10-25 06:09PM	Oncolytics Biotech Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital (PR Newswire) +24.56%
07:00AM	Oncolytics Biotech and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers (PR Newswire)
Mar-08-25 07:33AM	Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge (PR Newswire)
02:03AM	Oncolytics Biotech Inc (ONCY) Q4 2024 Earnings Call Highlights: Promising Cancer Study Results ... (GuruFocus.com)
Mar-07-25 07:00AM	Oncolytics Biotech Reports Highlights and Financial Results for Q4 and Year-End 2024 (PR Newswire) -6.29%
Mar-05-25 09:35AM	Oncolytics Biotech (ONCY) Loses -9.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +13.52%
Feb-27-25 10:10AM	Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 (PR Newswire)
Feb-25-25 07:00AM	Oncolytics Biotech to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights (PR Newswire)
Feb-19-25 10:10AM	Investors Eye Biotech Sector as Cancer Therapy Market Surges (PR Newswire)
07:00AM	Oncolytics Biotech Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025 (PR Newswire)
Feb-18-25 07:00AM	Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer (PR Newswire)
Feb-14-25 05:15PM	Oncolytics Biotech Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency (PR Newswire)
Feb-07-25 09:24PM	Oncolytics Biotech Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence (PR Newswire)
12:00PM	Loading…
Feb-05-25 12:00PM	Oncolytics Biotech (ONCY) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Jan-22-25 09:00AM	Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium (PR Newswire) +5.26%
07:00AM	Oncolytics Biotech to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium (PR Newswire)
Jan-16-25 11:17AM	German PEI approves enrolment in cohort 5 of Oncolytics pancreatic cancer trial (Clinical Trials Arena)
Jan-15-25 10:10AM	Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year (PR Newswire)
07:02AM	Regulatory Approval Clears Path for Oncolytics Biotech to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data (PR Newswire)
Dec-26-24 11:26AM	Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment (PR Newswire)
09:00AM	Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook (GlobeNewswire)
Dec-23-24 10:49AM	How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options (PR Newswire) +9.00%
07:00AM	Oncolytics Biotech Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data (PR Newswire)
Dec-20-24 12:52PM	Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses (PR Newswire) -6.36%
Dec-18-24 11:12AM	Cancer Care Disruptions Highlight Growing Demand for Innovative Oncology Treatments (PR Newswire)
08:45AM	Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic and Anal Cancers (GlobeNewswire)
07:00AM	Oncolytics Biotech to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium (PR Newswire)
Dec-03-24 07:00AM	Oncolytics Biotech Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial's New Pancreatic Cancer Cohort (PR Newswire)
Dec-02-24 10:18AM	Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend (PR Newswire)
Nov-14-24 08:00AM	Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon (PR Newswire)
Nov-13-24 02:08AM	Oncolytics Biotech Inc (ONCY) Q3 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com) -8.04%
Nov-12-24 07:00AM	Oncolytics Biotech Reports Third Quarter 2024 Financial Results and Operational Highlights (PR Newswire)
Nov-11-24 07:00AM	Oncolytics Biotech to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights (PR Newswire)
Oct-15-24 07:32AM	Breast Cancer Awareness Month Sees Biotech Advancements and Worrying Trends for Young Women (PR Newswire) +7.83%
Oct-07-24 11:21AM	Oncolytics targets accelerated approval for oncolytic virus therapy (Pharmaceutical Technology) +27.27%
Oct-04-24 09:00AM	FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket (PR Newswire) +18.22%
07:00AM	Oncolytics Biotech Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path (PR Newswire)
Sep-24-24 09:15AM	Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase (PR Newswire)
Sep-20-24 11:08AM	Global Cancer Rates Surge as Biotech Innovators Work on New Therapies (PR Newswire)
09:00AM	How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs (GlobeNewswire)
Sep-19-24 12:08PM	Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players (PR Newswire)
07:00AM	Oncolytics Biotech Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study (PR Newswire)
Sep-06-24 08:00AM	Oncolytics Biotech to Participate in Fireside Chats at Two Investment Conferences in September (PR Newswire)
Aug-12-24 04:37PM	Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates (PR Newswire)
07:45AM	Sernova Corp. Announces Appointment of New Chief Executive Officer (GlobeNewswire)
Aug-02-24 07:00AM	Oncolytics Biotech to Participate in a Fireside Chat at Canaccord Genuity's 44th Annual Growth Conference (PR Newswire)
Aug-01-24 04:01PM	Oncolytics Biotech Reports Second Quarter 2024 Financial Results and Operational Highlights (PR Newswire)
Jul-24-24 07:00AM	Oncolytics Biotech to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights (PR Newswire)
Jun-27-24 03:28PM	American Cancer Society Projects Over 2 Million New Cases in 2024: Biotech Innovations Respond (PR Newswire)
07:00AM	Oncolytics Biotech Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program (PR Newswire)
Jun-24-24 07:00AM	Oncolytics Biotech Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence (PR Newswire)
Jun-21-24 06:53AM	Oncolytics doses first subject in pancreatic cancer trial (Clinical Trials Arena)
Jun-20-24 05:26PM	Biotech Advances Propel Oncology Market to $564.5B Amid Youth Cancer Spike (PR Newswire)
10:00AM	Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth (GlobeNewswire)
08:45AM	Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033 (GlobeNewswire)
07:26AM	Oncolytics Biotech Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer (PR Newswire)
Jun-19-24 01:09PM	From Comfort to Cure: 2024 ASCO Meeting Reveals Groundbreaking Oncology Data (PR Newswire)
Jun-12-24 10:22AM	Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments (PR Newswire)
Jun-04-24 09:55AM	Oncolytics Biotech (ONCY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Jun-03-24 09:17AM	Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates (PR Newswire)
May-28-24 01:24PM	Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults (PR Newswire)
May-24-24 12:16PM	Emerging Trends in Oncology: ASCO 2024 Highlights Next-Gen Antibody-Drug Conjugates and More (PR Newswire)
08:45AM	Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032 (GlobeNewswire)
07:00AM	Oncolytics Biotech ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action (PR Newswire)
May-23-24 11:51AM	Pancreatic Cancer Battle Intensifies: Biotech Innovations Aim to Boost Survival Rates (PR Newswire)
May-17-24 12:50PM	Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment (PR Newswire)
May-16-24 07:00AM	Oncolytics Biotech Announces Voting Results from the Annual General Meeting of Shareholders (PR Newswire)
May-15-24 11:14AM	Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection (PR Newswire)
08:03AM	Oncolytics Biotech Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Pancreatic Cancer Trial (MT Newswires)
07:00AM	Oncolytics Biotech Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial (PR Newswire)
May-10-24 04:35PM	Oncolytics Biotech Inc. (NASDAQ:ONCY) Q1 2024 Earnings Call Transcript (Insider Monkey) -5.65%
May-09-24 08:59PM	ONCY Stock Earnings: Oncolytics Biotech Beats EPS for Q1 2024 (InvestorPlace) +5.08%
04:21PM	Oncolytics Biotech Reports a First-Quarter Loss of Near $7 Million (MT Newswires)
04:01PM	Oncolytics Biotech Reports First Quarter 2024 Financial Results and Operational Highlights (PR Newswire)
12:15PM	Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036 (PR Newswire)
10:26AM	Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb (PR Newswire)
08:08AM	Oncolytics Biotech Receives German Regulatory Clearance to Evaluate Pelareorep with Modified Folfirinox in Pancreatic Cancer (MT Newswires)
07:00AM	Oncolytics Biotech Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer (PR Newswire)
May-08-24 07:00AM	Oncolytics Biotech to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference (PR Newswire)
May-03-24 12:15PM	Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032 (PR Newswire)
Apr-30-24 10:30AM	As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response (PR Newswire)
07:00AM	Oncolytics Biotech to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights (PR Newswire)
Apr-25-24 07:00AM	Oncolytics Biotech Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting (PR Newswire)

Oncolytics Biotech, Inc. engages in the provision of development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolation of the reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ONCY

Oncolytics Biotech, Inc

Upgrade your FINVIZ experience